Trial site
Guangdong General Hospital
- 26running trials
- 13closed trials
The trials here
What the 39 trials at this site are about, from their registry records.
- Conditions
- Lung cancer18 trials
- Alzheimer disease2 trials
- Childhood cancers2 trials
- Mild cognitive impairment2 trials
- Multiple myeloma2 trials
- Triple-negative breast cancer2 trials
- ANCA-associated vasculitis1 trial
- Brain metastases1 trial
- Chronic lymphocytic leukaemia1 trial
- Colorectal cancer1 trial
- Diffuse large B-cell lymphoma1 trial
- Follicular lymphoma1 trial
- and 12 more
- Phase
- Phase 323 trials
- Phase 29 trials
- Phase 12 trials
- Phase 1/22 trials
- Phase 2/32 trials
- Phase 41 trial
- Status
- Completed13 trials
- Active, not recruiting12 trials
- Recruiting8 trials
- Not yet recruiting6 trials
- Lead sponsor
- Hoffmann-La Roche8 trials
- EMD Serono Research & Development Institute, Inc.4 trials
- Shanghai Junshi Bioscience Co., Ltd.3 trials
- Beijing InnoCare Pharma Tech Co., Ltd.2 trials
- Hutchmed2 trials
- and 18 more
Running trials
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Recruiting
Not yet recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Recruiting
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
Active, not recruiting
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Active, not recruiting
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer2 recruiting
- Alzheimer disease1 recruiting
- ANCA-associated vasculitis1 recruiting
- Childhood cancers1 recruiting
- Chronic lymphocytic leukaemia1 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- Follicular lymphoma1 recruiting
- Hearing loss1 recruiting
- IgA nephropathy1 recruiting
- Mild cognitive impairment1 recruiting
- Multiple myeloma1 recruiting
- Pancreatic cancer1 recruiting
- Sarcoma1 recruiting
- Triple-negative breast cancer1 recruiting
- Type 2 diabetes1 recruiting
Closed trials
Completed
Completed
Completed
Completed
Completed
Completed
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)
Completed
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Completed
Completed
Completed
Completed
Completed
Completed
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Site data: ClinicalTrials.govUpdated 13 Nov 2026